江苏诺泰澳赛诺生物制药股份有限公司

江苏诺泰澳赛诺生物制药股份有限公司

江苏省连云港经济技术开发区临浦路28号

2004

500以上

500,000,000至749,999,999

江苏诺泰澳赛诺生物制药股份有限公司成立于2009年，位于国家级连云港经济技术开发区，现有员工1100余人。公司于2021年5月20日在上海证券交易所科创板挂牌上市 (股票简称: 诺泰生物，代码: 688076)。诺泰生物是一家聚焦多肽、寡核苷酸药物及小分子化药的自主研发与定制研发相结合的国家高新技术企业和省级科技型企业。公司致力于通过技术创新，突破药物研发及生产的技术瓶颈，构建从医药高级中间体、原料药到制剂的全产业链，为全球合作伙伴提供绿色、低成本、优质、高效的医药相关产品和技术服务。

品牌,国际认证/标准,经验丰富的研发人员,发货速度,生产能力,产品线丰富,合同定制,接受买家的规格要求,接受小额订单,良好的信誉,优质服务

311121

CDMO PEPTIDE API PEPTIDE CDMO 多肽专家,国内最大的原料生产供应商。 FDA, NMPA cGMP Sinopep is specialized in the development and the manufacturing via solid phase peptide synthsis and liquid phase peptide synthesis. From technical aspect, we have expertise technology of peptide products both in LPPS and SPPS field. We can adopt the LPPS and SPPS strategoes together for manufacturing peptide products. Such as , Liraglutide and semaglutide projects: We synthesize main chain through SPPS strategy; meanwhile, we obtain side chain and segments via LPPS. From manufacturing aspect, providing CDMO service from research scale(gram-scale batch) to bulk cGMP Active Pharmaceutical Ingredient (API)(kg-scale batch-10kg-scale batch) . The manufacturing capability of Sinopep is biggest in China at this time. From regulatory aspect, Sinopep has a strong regulatory background and we are well prepared to fully support you required regulatory documentation such as DMF and technical package. Eptifibatide and bivalirudin DP from our end users are commercialized in EU and US market. Thymalfasin and Octreotide are commercial in China market.

制造商,出口商

北美洲,中/南美洲,西欧,东欧,大洋洲,亚洲,中东,非洲

Semaglutide;Liraglutide;Tirzepatide;Bivalirudin;Eptifibatide;Octreotide Acetate;Lanreotide Acetate;Cetrorelix Acetate;Desmopressin Acetate;Atosiban Acetate;Retatrutide;Pegcetacoplan;Cagrilintide;Fulvestrant;Oseltamivir Phosphate;Alogliptin Benzoate;Epalrestat;Sodium Picosulfate;Atorvastatin Calcium;Bumetanide;Sulindac;Risdiplam;Elacestrant;Dydrogesterone;Bifonazole;Slidenafil Citrate;Decoquinate;Ezetimibe;Roxadustat;Ubrogepant;Rimegepant;Baloxavir Marboxil;Orforglipron;Lumateperone Tosylate;Avacopan;Nusinersen;Inclisiran

第二十三届世界制药原料中国展

2025-03-06至2025-07-31

E2A16

Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Finished Dosage;CMO & CRO;Biotech;Veterinary Drug & Feed Additives